Korean J Gastroenterol.  2024 Aug;84(2):35-42. 10.4166/kjg.2024.060.

Old and New Biologics and Small Molecules in Inflammatory Bowel Disease: Anti-Tumor Necrosis Factors

• Kim SU
• Lee HS

• KMID: 2558903
• DOI: http://doi.org/10.4166/kjg.2024.060

Abstract

Inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, is a chronic condition characterized by relapsing and remitting inflammation of the gastrointestinal tract. The pathogenesis involves a complex interplay of genetic, environmental, and immune factors. Treatment paradigms have evolved significantly over the past few decades, with the introduction of biologics, particularly anti-TNF (tumor necrosis factor) agents, marking a significant advancement. Anti-TNF therapies, including infliximab, adalimumab, golimumab, and certolizumab pegol, have efficacy in inducing and maintaining remission, promoting mucosal healing, and improving the quality of life in moderate to severe IBD patients. The early and appropriate use of these agents can mitigate disease progression and reduce the dependency on corticosteroids, enhancing long-term patient outcomes. Nevertheless, these therapies are expensive and are associated with potential adverse effects, including increased risk of infections and malignancies. This review discusses the mechanisms, clinical efficacy, safety profiles, and therapeutic positioning of anti-TNF agents in IBD management, integrating current Korean treatment guidelines.

Keyword

Inflammatory bowel disease; Ulcerative colitis; Crohn's disease; Tumor necrosis factor-α inhibitor

Reference

1. Baumgart DC, Sandborn WJ. 2007; Inflammatory bowel disease: clinical aspects and established and evolving therapies. Lancet. 369:1641–1657. DOI: 10.1016/S0140-6736(07)60751-X. PMID: 17499606.

2. Xavier RJ, Podolsky DK. 2007; Unravelling the pathogenesis of inflammatory bowel disease. Nature. 448:427–434. DOI: 10.1038/nature06005. PMID: 17653185.

3. Jostins L, Ripke S, Weersma RK, et al. 2012; Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature. 491:119–124. DOI: 10.1038/nature11582. PMID: 23128233. PMCID: PMC3491803.

4. Baumgart DC, Carding SR. 2007; Inflammatory bowel disease: cause and immunobiology. Lancet. 369:1627–1640. DOI: 10.1016/S0140-6736(07)60750-8. PMID: 17499605.

5. Feuerstein JD, Cheifetz AS. 2017; Crohn disease: Epidemiology, diagnosis, and management. Mayo Clin Proc. 92:1088–1103. DOI: 10.1016/j.mayocp.2017.04.010. PMID: 28601423.

6. Ungaro R, Mehandru S, Allen PB, Peyrin-Biroulet L, Colombel JF. 2017; Ulcerative colitis. Lancet. 389:1756–1770. DOI: 10.1016/S0140-6736(16)32126-2. PMID: 27914657.

7. Morrow T, Felcone LH. 2004; Defining the difference: What Makes Biologics Unique. Biotechnol Healthc. 1:24–29.

8. Ng SC, Shi HY, Hamidi N, et al. 2017; Worldwide incidence and prevalence of inflammatory bowel disease in the 21st century: a systematic review of population-based studies. Lancet. 390:2769–2778. DOI: 10.1016/S0140-6736(17)32448-0. PMID: 29050646.

9. Hong SW, Ye BD. 2020; The first step to unveil the epidemiology of inflammatory bowel disease in Central Asia. Intest Res. 18:345–346. DOI: 10.5217/ir.2020.00121. PMID: 33131230. PMCID: PMC7609391.

10. Song EM, Yang SK. 2022; Natural history of inflammatory bowel disease: a comparison between the East and the West. Intest Res. 20:418–430. DOI: 10.5217/ir.2021.00104. PMID: 34852421. PMCID: PMC9650334.

11. Kwak MS, Cha JM, Lee HH, et al. 2019; Emerging trends of inflammatory bowel disease in South Korea: A nationwide population-based study. J Gastroenterol Hepatol. 34:1018–1026. DOI: 10.1111/jgh.14542. PMID: 30447025.

12. Levin AD, Wildenberg ME, van den Brink GR. 2016; Mechanism of action of anti-TNF therapy in inflammatory bowel disease. J Crohns Colitis. 10:989–997. DOI: 10.1093/ecco-jcc/jjw053. PMID: 26896086.

13. Targan SR, Hanauer SB, van Deventer SJ, et al. 1997; A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med. 337:1029–1035. DOI: 10.1056/NEJM199710093371502. PMID: 9321530.

14. Hanauer SB, Feagan BG, Lichtenstein GR, et al. 2002; Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet. 359:1541–1549. DOI: 10.1016/S0140-6736(02)08512-4. PMID: 12047962.

15. Sands BE, Anderson FH, Bernstein CN, et al. 2004; Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med. 350:876–885. DOI: 10.1056/NEJMoa030815. PMID: 14985485.

16. Colombel JF, Sandborn WJ, Reinisch W, et al. 2010; Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med. 362:1383–1395. DOI: 10.1056/NEJMoa0904492. PMID: 20393175.

17. Rutgeerts P, Sandborn WJ, Feagan BG, et al. 2005; Infliximab for induction and maintenance therapy for ulcerative colitis. N Engl J Med. 353:2462–2476. DOI: 10.1056/NEJMoa050516. PMID: 16339095.

18. Jørgensen KK, Olsen IC, Goll GL, et al. 2017; Switching from originator infliximab to biosimilar CT-P13 compared with maintained treatment with originator infliximab (NOR-SWITCH): a 52-week, randomised, double-blind, non-inferiority trial. Lancet. 389:2304–2316. DOI: 10.1016/S0140-6736(17)30068-5. PMID: 28502609.

19. Schreiber S, Ben-Horin S, Leszczyszyn J, et al. 2021; Randomized controlled trial: Subcutaneous vs intravenous infliximab CT-P13 maintenance in inflammatory bowel disease. Gastroenterology. 160:2340–2353. DOI: 10.1053/j.gastro.2021.02.068. PMID: 33676969.

20. Hanauer SB, Sandborn WJ, Rutgeerts P, et al. 2006; Human anti-tumor necrosis factor monoclonal antibody (adalimumab) in Crohn's disease: the CLASSIC-I trial. Gastroenterology. 130:323–333. quiz 591DOI: 10.1053/j.gastro.2005.11.030. PMID: 16472588.

21. Sandborn WJ, Hanauer SB, Rutgeerts P, et al. 2007; Adalimumab for maintenance treatment of Crohn's disease: results of the CLASSIC II trial. Gut. 56:1232–1239. DOI: 10.1136/gut.2006.106781. PMID: 17299059. PMCID: PMC2701613.

22. Colombel JF, Sandborn WJ, Rutgeerts P, et al. 2007; Adalimumab for maintenance of clinical response and remission in patients with Crohn's disease: the CHARM trial. Gastroenterology. 132:52–65. DOI: 10.1053/j.gastro.2006.11.041. PMID: 17241859.

23. Sandborn WJ, Rutgeerts P, Enns R, et al. 2007; Adalimumab induction therapy for Crohn disease previously treated with infliximab: a randomized trial. Ann Intern Med. 146:829–838. DOI: 10.7326/0003-4819-146-12-200706190-00159. PMID: 17470824.

24. Rutgeerts P, Van Assche G, Sandborn WJ, et al. 2012; Adalimumab induces and maintains mucosal healing in patients with Crohn's disease: data from the EXTEND trial. Gastroenterology. 142:1102–1111.e2. DOI: 10.1053/j.gastro.2012.01.035. PMID: 22326435.

25. Sandborn WJ, van Assche G, Reinisch W, et al. 2012; Adalimumab induces and maintains clinical remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 142:257–265.e1-3. DOI: 10.1053/j.gastro.2011.10.032. PMID: 22062358.

26. Sandborn WJ, Feagan BG, Marano C, et al. 2014; Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 146:85–95. quiz e14–5. DOI: 10.1053/j.gastro.2013.05.048. PMID: 23735746.

27. Sandborn WJ, Feagan BG, Marano C, et al. 2014; Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis. Gastroenterology. 146:96–109.e1. DOI: 10.1053/j.gastro.2013.06.010. PMID: 23770005.

28. Sandborn WJ, Feagan BG, Stoinov S, et al. 2007; Certolizumab pegol for the treatment of Crohn's disease. N Engl J Med. 357:228–238. DOI: 10.1056/NEJMoa067594. PMID: 17634458.

29. Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. 2007; Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 357:239–250. DOI: 10.1056/NEJMoa062897. PMID: 17634459.

30. Hébuterne X, Lémann M, Bouhnik Y, et al. 2013; Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol. Gut. 62:201–208. DOI: 10.1136/gutjnl-2012-302262. PMID: 22525883. PMCID: PMC3551215.

31. Park JJ, Yang SK, Ye BD, et al. 2017; Second Korean guidelines for the management of Crohn's disease. Intest Res. 15:38–67. DOI: 10.5217/ir.2017.15.1.38. PMID: 28239314. PMCID: PMC5323307.

32. Choi CH, Moon W, Kim YS, et al. 2017; Second Korean guidelines for the management of ulcerative colitis. Intest Res. 15:7–37. DOI: 10.5217/ir.2017.15.1.7. PMID: 28239313. PMCID: PMC5323310.

33. Antoni C, Braun J. 2002; Side effects of anti-TNF therapy: current knowledge. Clin Exp Rheumatol. 20(6 Suppl 28):S152–157.

34. Laharie D, Bourreille A, Branche J, et al. 2012; Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial. Lancet. 380:1909–1915. DOI: 10.1016/S0140-6736(12)61084-8. PMID: 23063316.

35. Vavricka SR, Scharl M, Gubler M, Rogler G. 2014; Biologics for extraintestinal manifestations of IBD. Curr Drug Targets. 15:1064–1073. DOI: 10.2174/1389450115666140908125453. PMID: 25198785.

36. Singh S, Fumery M, Sandborn WJ, Murad MH. 2018; Systematic review and network meta-analysis: first- and second-line biologic therapies for moderate-severe Crohn's disease. Aliment Pharmacol Ther. 48:394–409. DOI: 10.1111/apt.14852. PMID: 29920733.

37. Singh S, Fumery M, Sandborn WJ, Murad MH. 2018; Systematic review with network meta-analysis: first- and second-line pharmacotherapy for moderate-severe ulcerative colitis. Aliment Pharmacol Ther. 47:162–175. DOI: 10.1111/apt.14422. PMID: 29205406.